Your browser is no longer supported. Please, upgrade your browser.
GSK GlaxoSmithKline plc daily Stock Chart
GlaxoSmithKline plc
Index- P/E48.93 EPS (ttm)0.89 Insider Own0.20% Shs Outstand2.44B Perf Week-0.21%
Market Cap105.59B Forward P/E15.16 EPS next Y2.86 Insider Trans0.00% Shs Float2.44B Perf Month6.18%
Income2.17B PEG3.73 EPS next Q0.69 Inst Own9.40% Short Float0.19% Perf Quarter4.01%
Sales37.57B P/S2.81 EPS this Y-89.20% Inst Trans3.35% Short Ratio1.55 Perf Half Y12.61%
Book/sh0.91 P/B47.58 EPS next Y1.31% ROA2.90% Target Price47.55 Perf Year3.07%
Cash/sh2.44 P/C17.76 EPS next 5Y13.10% ROE188.80% 52W Range37.20 - 45.58 Perf YTD12.44%
Dividend1.95 P/FCF613.88 EPS past 5Y-28.90% ROI8.60% 52W High-5.00% Beta0.99
Dividend %4.50% Quick Ratio0.60 Sales past 5Y0.40% Gross Margin68.40% 52W Low16.40% ATR0.43
Employees99827 Current Ratio0.90 Sales Q/Q18.50% Oper. Margin12.40% RSI (14)64.15 Volatility0.98% 0.92%
OptionableYes Debt/Eq10.70 EPS Q/Q271.90% Profit Margin5.80% Rel Volume1.14 Prev Close43.60
ShortableYes LT Debt/Eq8.52 EarningsApr 26 Payout232.70% Avg Volume2.97M Price43.30
Recom2.00 SMA203.03% SMA503.25% SMA2005.35% Volume3,394,320 Change-0.69%
Apr-05-17Upgrade Exane BNP Paribas Underperform → Neutral
Mar-09-17Initiated Liberum Buy
Mar-09-17Initiated Kepler Reduce
Oct-20-16Initiated Investec Buy
Sep-23-16Initiated Piper Jaffray Overweight
Jul-14-16Upgrade Jefferies Hold → Buy
Mar-30-16Upgrade Citigroup Neutral → Buy
Feb-26-16Initiated Cantor Fitzgerald Hold
Dec-09-15Upgrade BofA/Merrill Neutral → Buy
Dec-07-15Reiterated Argus Buy $52 → $48
Oct-20-15Upgrade Credit Suisse Underperform → Neutral
Sep-15-15Upgrade Exane BNP Paribas Underperform → Neutral
Sep-08-15Upgrade BofA/Merrill Underperform → Neutral
Jun-26-15Upgrade Liberum Sell → Hold
Jun-04-15Downgrade Morgan Stanley Overweight → Equal-Weight
May-20-15Resumed Citigroup Neutral
Apr-15-15Initiated Societe Generale Sell
Feb-19-15Reiterated Argus Buy $55 → $52
Aug-08-14Reiterated Argus Buy $65 → $55
Apr-23-14Upgrade Argus Hold → Buy
May-21-17 06:41AM  Better Buy: Celldex Therapeutics, Inc. vs. Agenus Inc. Motley Fool
May-16-17 05:57PM  Ionis (IONS) Stock Falls Despite Positive Inotersen Data Zacks
11:15AM  Citi Prefers These 4 Stocks Over Pfizer On Bottom-Line Concerns Benzinga
08:00AM  Today's Research Reports on Stocks to Watch: GlaxoSmithKline and Novartis Accesswire
May-15-17 08:27AM  GlaxoSmithKline Could Buy Out Partner Novartis
May-12-17 11:56AM  Top-10 Glaxo investor Woodford sells out, criticises board Reuters
09:59AM  Glaxit: GlaxoSmithKline Sees a Top Investor Dump Stock out of 'Frustration'
08:05AM  Woodford Turns Bullish on Lloyds as He Cuts Ties With Glaxo Bloomberg
May-11-17 03:16PM  [$$] SuperGroup's wholesale change translates into sales Financial Times
03:38AM  Hikma Shares Plunge After It Says 'Low Likelihood' of 2017 Generic Advair Approval
May-10-17 03:25PM  Mylan disagrees with FDA over generic Advair delay Reuters
01:25PM  GlaxoSmithKline Plc : GSK-US: Dividend Analysis : May 12th, 2017 (record date) : By the numbers : May 10, 2017 Capital Cube
12:28PM  Better Buy: GlaxoSmithKline vs. Johnson & Johnson Motley Fool
11:37AM  Mylan says disagrees with FDA over generic Advair delay Reuters
10:59AM  FTSE 100 flirts with 7-week high as oil shares climb MarketWatch
May-09-17 09:50AM  Epizyme (EPZM) Incurs Narrower-than-Expected Loss in Q1 Zacks
May-06-17 07:25AM  Which Big Pharma Is the Best Dividend Stock? Motley Fool
May-05-17 01:12PM  Agenus (AGEN) Reports Narrower-than-Expected Loss in Q1 Zacks
08:23AM  GSK 'real world' drug test has second success in asthma Reuters
07:38AM  Relvar Ellipta Significantly Improved Asthma Control in Salford Lung Study Patients Compared with Their Usual Care Business Wire
May-04-17 07:40AM  Here's What Wiped $3 Billion Off GlaxoSmithKline's Market Cap in April Motley Fool
May-03-17 07:36AM  Whats GlaxoSmithKlines Valuation after 1Q17 Earnings? Market Realist
May-02-17 11:10AM  Cambridge's bluebird bio licenses delivery tech to Novartis, GSK American City Business Journals
10:36AM  How GlaxoSmithKlines Consumer Healthcare Segment Fared in 1Q17 Market Realist
09:07AM  How GlaxoSmithKlines Vaccines Business Performed in 1Q17 Market Realist
07:38AM  Analyzing GlaxoSmithKlines Global Pharmaceutical Performance Market Realist
May-01-17 03:57PM  ETFs with exposure to GlaxoSmithKline Plc : May 1, 2017 Capital Cube
01:41PM  3 Bargain-Bin High-Yield Dividend Stocks You've Overlooked This Spring Motley Fool
12:36PM  GlaxoSmithKline making $139M investment in Rockville plant American City Business Journals
11:30AM  Triad college awarded $25,000 STEM grant American City Business Journals
10:39AM  How Did GlaxoSmithKlines HIV Business Perform in 1Q17? Market Realist
09:42AM  Is This Big Pharma Stock's Sky-High Dividend Yield Sustainable? Motley Fool
09:09AM  How Did GlaxoSmithKlines Pharmaceuticals Segment Do in 1Q17? Market Realist
07:40AM  How GlaxoSmithKlines Business Segments Performed in 1Q17 Market Realist
07:37AM  Novartiss Valuation after 1Q17 Earnings Market Realist
Apr-28-17 04:45PM  GlaxoSmithKlines 1Q17 Earnings Surpass Analysts Estimates Market Realist
11:12AM  GlaxoSmithKline Plc :GSK-US: Earnings Analysis: Q1, 2017 By the Numbers : April 28, 2017 Capital Cube
Apr-27-17 04:37PM  Glaxo (GSK) Reports In-Line Q1 Earnings, Reiterates View Zacks
12:05AM  New Glaxo Boss Emma Walmsley Seeks Sharper R&D Edge The Wall Street Journal
Apr-26-17 10:55AM  New GlaxoSmithKline CEO wants fewer, bigger new drug launches Reuters
10:36AM  Analyst Ratings and Recommendations for GlaxoSmithKline Market Realist
10:26AM  Glaxo meets 1Q profit forecasts Associated Press
10:01AM  Ionis Pharmaceuticals: Big Data Coming Soon Motley Fool
09:46AM  Glaxo Stock Slumps as Investors Eye Advair Generics
09:11AM  Glaxo (GSK) Beats Earnings and Revenues in Q1 Zacks
09:07AM  GlaxoSmithKlines 1Q17 Estimates: Consumer Healthcare Market Realist
08:57AM  GlaxoSmithKline Beats Q1 Estimates, Keeps Full Year Targets In Place
08:31AM  GSK warns of impact from generic drugs after solid Q1 Associated Press
08:25AM  [$$] GlaxoSmithKline Net Income Boosted by Strong Sales, Weak Pound The Wall Street Journal
07:36AM  GlaxoSmithKlines 1Q17 Estimates: Vaccines Business Market Realist
07:13AM  Glaxo's New CEO Walmsley Pledges to Make Drugs the Priority Bloomberg
07:13AM  Glaxo Profit Jumps 31% as Sales of HIV, Lung Drugs Increase Bloomberg
07:10AM  Weak sterling boosts GlaxSmithKline as new CEO takes over Reuters
Apr-25-17 03:01PM  [$$] GlaxoSmithKline 1Q Results Expected to Get Boost From Weak Pound The Wall Street Journal
10:39AM  GlaxoSmithKlines 1Q17 Estimates: Pharmaceuticals Segment Market Realist
09:09AM  GlaxoSmithKlines 1Q17 Estimates: Revenues Expected to Grow Market Realist
07:40AM  GlaxoSmithKlines 1Q17 Earnings: Analysts Estimates Market Realist
06:50AM  Drug Stocks Q1 Earnings Releases on Apr 26: AMGN, GSK & More Zacks
Apr-24-17 12:30PM  First malaria vaccine to be tested in Africa, with boost from Lexington's Agenus American City Business Journals
Apr-22-17 12:03PM  3 Dividend Stocks That Retirees Should Avoid Motley Fool
Apr-21-17 04:52PM  Barclays -- Mired In Mud (Again) -- Should Dump Its CEO Forbes
01:13PM  Analyst Estimates for Novartiss 1Q17 Earnings Market Realist
11:21AM  What's in Store for GlaxoSmithKline (GSK) in Q1 Earnings? Zacks
07:07AM  4 Stocks Are Showing Red Flags -- Here's When to Sell
12:00AM  $3M award in suit against drug company over man's suicide Associated Press
Apr-20-17 06:43PM  Teva's new asthma inhaler poses first competition for GSK's Advair Reuters
06:08PM  Here's Why Innoviva Inc. Lost 10% Today Motley Fool
05:38PM  GSK must pay $3 million in generic Paxil suicide lawsuit: U.S. jury Reuters
05:32PM  GSK must pay $3 mln in generic Paxil suicide lawsuit: U.S. jury Reuters
02:35PM  As Price Falls, Vetr Upgrades GlaxoSmithKline To Buy Benzinga
01:34PM  Teva launches copy of asthma inhaler Advair Reuters
09:42AM  Innoviva director vote drama hands last-minute loss to Sarissa Reuters
12:30AM  ZappRX gets $25 million from Qiming US to expand into the U.S. drug prescription market TechCrunch
Apr-19-17 10:09PM  Activist Sarissa says Innoviva backed out of proxy settlement deal Reuters
Apr-18-17 09:39PM  There Have Been Few Losers Since The Brexit Vote, But It's About To Get Ugly Forbes
07:15PM  [$$] Science looks to nucleic acids to create right genetic vaccine recipe Financial Times
08:15AM  Blog Coverage Bristol-Myers and Nordic Announce an Agreement for Development of Fibrosis Biomarker Technology Accesswire
Apr-17-17 10:43AM  OncoMed's lung cancer drug fails mid-stage study, shares tumble Reuters
Apr-13-17 05:35PM  Innoviva to review costs, executive pay following Sarissa pressure Reuters
Apr-12-17 08:04AM  This Survey's Bad News Could Be Good News for Inovio Pharmaceuticals, Inc. Motley Fool
Apr-11-17 06:15AM  Hearing loss biotech Frequency Therapeutics dials up $32M round American City Business Journals
06:00AM  The State of Play in Axovant Sciences Investopedia
Apr-09-17 03:03PM  The 3 Best HIV Drug Stocks to Buy in 2017 Motley Fool
Apr-08-17 12:03PM  GlaxoSmithKline Dodges a Bullet... for Now Motley Fool
07:22AM  3 Big Pharma Companies With the Best Pipelines Motley Fool
Apr-06-17 09:41AM  4 Big Reasons Mylan N.V. Shares Fell 7% in March Motley Fool
05:00AM  Just How Much Is a Medical Miracle Worth? Bloomberg
Apr-05-17 04:21PM  Better Buy: AbbVie Inc. vs. GlaxoSmithKline Motley Fool
02:49PM  At Least 33 Companies Have Pulled Ads From 'The O'Reilly Factor' in Wake of Sexual Harassment Claims
08:50AM  GlaxoSmithKline Is Voluntarily Recalling Asthma Inhalers in the U.S.
Apr-03-17 04:11PM  GlaxoSmithKline Initiates Phase III Study with Mepolizumab Zacks
09:06AM  Novartis Expects to Witness Flat Revenue Growth in 2017
08:25AM  Wall Street Loves European Stocks: 5 Top Dividend Picks to Buy Now 24/7 Wall St.
07:36AM  How Eli Lillys New Products Performed in 2016
Apr-02-17 12:18PM  [$$] At Glaxo, a New CEO Steps In, Must Wring More From R&D at The Wall Street Journal
Apr-01-17 08:45AM  50 Advertisers Boycott YouTube Advertising, And It Won't Mean More Than A 1% Dip In Google's Top Line Benzinga
06:41AM  The Worst-Case Scenario for Gilead Sciences, Inc. Motley Fool
12:08AM  [$$] Glaxos New CEO Is a Steady Hand in Pharmaceuticals Rolling Seas The Wall Street Journal
Mar-31-17 03:29PM  Understanding Sanofis Valuation Compared to Peers Market Realist
07:21AM  Pharma Stock Roundup: FDA Nod for SNY, Roche Drugs, Generic Advair Relief for GSK?
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, vaccines, and HIV, as well as oncology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories under the Otrivin, Panadol, parodontax, Poligrip, Sensodyne, Theraflu, and Voltaren brand names. The company offers its consumer healthcare products in the form of tablets, caplets, infant syrup drops, topical gels, nasal sprays, effervescents, lozenges, gum and trans-dermal patches, malted drinks and foods, and topical creams and non-medicated patches, as well as toothpastes, toothbrushes, mouth rinses, medicated mouthwashes, gels and sprays, denture adhesives, and denture cleansers. GlaxoSmithKline plc was founded in 1935 and is headquartered in Brentford, the United Kingdom.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GLAXOSMITHKLINE PLC10% OwnerOct 24Buy14.0066,500931,0003,220,627Oct 26 05:49 PM